Biohaven's Epilepsy Drug Faces FDA Hold Days After $350M Deal
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests.
This announcement comes just weeks after Biohaven sold off rights to the therapy, which is covered by a pending $350 million deal.
Biohaven
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — FDA places partial hold on Biohaven’s epilepsy drug“The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests, dealing a blow to an asset covered by a pending $350 million”
fierce biotech — <a href="/biotech/biohaven-drug-suffers-fda-hold-days-after-attracting-350m-deal" hreflang="en">Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal</a>